Publication:
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib

Simple item page
dc.contributor.authorÇİÇEK, FURKAN CUMA
dc.contributor.authorsDemircan, Nazim C.; Alan, Ozkan; Tuylu, Tugba Basoglu; Telli, Tugba Akin; Arikan, Rukiye; Cicek, Furkan C.; Ercelep, Ozlem; Ozturk, Mehmet A.; Cetin, Ilknur Alsan; Ergelen, Rabia; Tinay, Ilker; Babacan, Nalan Akgul; Kaya, Serap; Dane, Faysal; Yumuk, Perran F.
dc.date.accessioned2022-03-12T22:38:07Z
dc.date.available2022-03-12T22:38:07Z
dc.date.issued2020
dc.description.abstractBackground Anti-angiogenic tyrosine kinase inhibitors, sunitinib and pazopanib, have proven efficacy in advanced renal cell carcinoma, with specific adverse events occurring during treatment process. Comorbidities can reflect functional status and have prognostic value in oncology patients. We aimed to assess the association of the Charlson Comorbidity Index with severe toxicities and mortality in renal cell carcinoma cases treated with front-line sunitinib or pazopanib. Methods Files of locally advanced and metastatic renal cell carcinoma patients who received first-line sunitinib or pazopanib were retrospectively examined. Charlson Comorbidity Index of each patient was calculated. Patients were also stratified into Memorial Sloan-Kettering Cancer Center risk groups. Predictors of dose-limiting toxicity were evaluated with binomial logistic regression analysis. Univariate and multivariate Cox regression models were utilized to determine prognostic factors for survival. Results The study included 102 patients, 64 were treated with first-line sunitinib and 38 with pazopanib. In 42 patients (41.9%), Charlson Comorbidity Index was 9 or more. Dose-limiting toxicities were significantly more frequent in Charlson Comorbidity Index >= 9 group (69% vs. 40%, p = 0.004), and Charlson Comorbidity Index independently predicted dose-limiting toxicity (Hazard ratio (HR) = 4.30, p = 0.002). After adjusting for other variables, a Charlson Comorbidity Index of >= 9 is also a significant prognostic factor for progression-free (HR = 1.76, p = 0.02) and overall survival (HR = 1.75, p = 0.03). Conclusions Charlson Comorbidity Index may be a valuable method to estimate prognosis and optimize therapy in patients with advanced renal cell carcinoma receiving first-line sunitinib or pazopanib.
dc.identifier.doi10.1177/1078155219890032
dc.identifier.eissn1477-092X
dc.identifier.issn1078-1552
dc.identifier.pubmed31793376
dc.identifier.urihttps://hdl.handle.net/11424/235502
dc.identifier.wosWOS:000500667300001
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCharlson Comorbidity Index
dc.subjectdose-limiting toxicity
dc.subjectprognostic factor
dc.subjectrenal cell carcinoma
dc.subjecttyrosine kinase inhibitor
dc.subjectINTERFERON-ALPHA
dc.subjectDOUBLE-BLIND
dc.subjectPHASE-III
dc.subjectCANCER
dc.subjectNEPHRECTOMY
dc.titleImpact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib
dc.typearticle
dspace.entity.typePublication
local.avesis.id6680e782-05f5-413b-9b30-a221d669adae
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber1078155219890030
local.journal.numberofpages9
local.journal.quartileQ4
oaire.citation.endPage1155
oaire.citation.issue5
oaire.citation.startPage1147
oaire.citation.titleJOURNAL OF ONCOLOGY PHARMACY PRACTICE
oaire.citation.volume26
relation.isAuthorOfPublication6ec07c7a-dd39-4505-9a11-60bc1f9602ac
relation.isAuthorOfPublication.latestForDiscovery6ec07c7a-dd39-4505-9a11-60bc1f9602ac

Files

Collections

Research Outputs